Ali Saied, McDermott Sinead
Department of Clinical Microbiology, St. Vincent's University Hospital, Dublin, Ireland.
Infect Prev Pract. 2023 Jul 21;5(3):100300. doi: 10.1016/j.infpip.2023.100300. eCollection 2023 Sep.
is the foremost cause of nosocomial infectious diarrhoea and one of the most prevalent healthcare associated infections (HAIs).
To investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on the incidence of healthcare associated infection (HA-CDI).
A retrospective study was conducted from January 2019-December 2022 inclusive at a tertiary University Hospital in Dublin, Ireland. The study period was divided into COVID-19 and non-COVID-19 periods determined in tangent with the then national incidences of COVID-19 and number of hospitalized patients with COVID-19. Analyses looked at quantity of testing performed, incidence rates and antimicrobial consumption. An independent samples t-test was used to determine significance between groups.
Between COVID-19 and non-COVID-19 periods, no statistically significant difference was observed among HA-CDI rates per 10,000 bed-days (2.1 cases vs 1.76 cases; =0.34), consumption of defined daily doses per 100 bed-days of antimicrobials - all antimicrobials (83.36 vs 89.5; =0.091), fluoroquinolones only (3.71 vs 4.46; =0.067), third-generation cephalosporins only (4.17 vs 4.43; =0.449), carbapenems only (3.28 vs 3.26; =0.944) - or the number of tests performed per 10,000 bed-days (321.81 tests vs 326.63 tests; =0.696).
There was no difference in the incidence rates of HA-CDI between COVID-19 and non-COVID-19 periods at our institution.
是医院感染性腹泻的首要原因，也是最常见的医疗相关感染（HAIs）之一。
调查2019年冠状病毒病（COVID-19）大流行对医疗相关感染（HA-CDI）发病率的影响。
在爱尔兰都柏林的一家三级大学医院进行了一项回顾性研究，研究时间为2019年1月至2022年12月。研究期分为COVID-19期和非COVID-19期，这与当时该国的COVID-19发病率和COVID-19住院患者数量相关。分析内容包括检测数量、发病率和抗菌药物消耗情况。采用独立样本t检验确定组间差异是否具有统计学意义。
在COVID-19期和非COVID-19期之间，每10000床日的HA-CDI发生率（2.1例对1.76例；P = 0.34）、每100床日抗菌药物的限定日剂量消耗量——所有抗菌药物（83.36对89.5；P = 0.091）、仅氟喹诺酮类药物（3.71对4.46；P = 0.067）、仅第三代头孢菌素（4.17对4.43；P = 0.449）、仅碳青霉烯类药物（3.28对3.26；P = 0.944）——或每10000床日的检测数量（321.81次检测对326.63次检测；P = 0.696）均未观察到统计学上的显著差异。
在我们机构，COVID-19期和非COVID-19期之间的HA-CDI发病率没有差异。
